However, only 15 patients with Grade 2–3 gliomas (8 IDH1-mutant and 7 with wildtype) were selected for subsequent analysis of blood flow in the subgroups of mutant and wildtype gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.